Immunic (NASDAQ:IMUX – Get Free Report) is expected to release its Q1 2025 earnings data before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of ($0.26) per share for the quarter.
Immunic Price Performance
Shares of NASDAQ IMUX opened at $0.99 on Tuesday. The company has a 50-day moving average price of $1.07 and a 200-day moving average price of $1.09. The stock has a market capitalization of $94.54 million, a P/E ratio of -0.80 and a beta of 1.73. Immunic has a 1 year low of $0.83 and a 1 year high of $2.11.
Analyst Ratings Changes
A number of equities analysts have issued reports on the company. StockNews.com downgraded Immunic from a “hold” rating to a “sell” rating in a research note on Thursday, March 20th. B. Riley reaffirmed a “buy” rating and set a $6.00 target price on shares of Immunic in a research report on Wednesday, April 16th. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Immunic in a report on Thursday, May 1st. D. Boral Capital restated a “buy” rating and set a $17.00 price objective on shares of Immunic in a research note on Wednesday, April 30th. Finally, William Blair began coverage on shares of Immunic in a research note on Tuesday, March 25th. They issued an “outperform” rating for the company. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $13.20.
Immunic Company Profile
Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Read More
- Five stocks we like better than Immunic
- Stock Market Upgrades: What Are They?
- Palantir’s Latest Deal Could Put a Freeze on Its Stock Price
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- 4 Automaker Stocks React to Tariffs: Winners and Losers
- What is a Special Dividend?
- Here’s Why Call Option Traders Love Dutch Bros Stock
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.
